On Wednesday, 12 March 2025, Amneal Pharmaceuticals (NASDAQ: AMRX) participated in the Barclays 27th Annual Global Healthcare Conference 2025, where Chairman and CEO Chirag Patel outlined the ...

Q4 2024 Management View Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four ...

On Wednesday, 12 March 2025, Amneal Pharmaceuticals (NASDAQ: AMRX) participated in the Barclays 27th Annual Global Healthcare Conference 2025, where Chairman and CEO Chirag Patel outlined the ...

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty ...

Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four times, and notable ...

BRIDGEWATER, N.J., January 29, 2025--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 BRIDGEWATER, N.J., January 23, 2025--Amneal ...

“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and ...

BRIDGEWATER, N.J. (AP) — BRIDGEWATER, N.J. (AP) — Amneal Pharmaceuticals, Inc. (AMRX) on Friday reported a loss of $31.1 million in its fourth quarter. The Bridgewater, New Jersey-based ...